TFF3 expression, ARID1A loss and beta-catenin expression had 100% specificity in diagnosing grade 3 endometrioid carcinoma, but relatively low sensitivity at 37%, 33%, and 7%, respectively. The gene discussed is ARID1A; the disease is endometrioid adenocarcinoma.